Avinashnarayan Venkatanarayan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Avinashnarayan Venkatanarayan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alan P. Venook
Helen Diller Family Comprehensive Cancer Center 1 San Francisco, California
1 shared publication - Anneleen Daemen
Department of Bioinformatics & Computational Biology, Genentech, Inc
1 shared publication - Carlos Bais
Genentech, Inc, South San Francisco, USA
1 shared publication Chris Bolen
Bioinformatics & Computational Biology, Genentech, Inc., South San Francisco, USA
1 shared publicationChu-Fang Lin
Real World Data Science Analytics, Genentech, Inc., South San Francisco, USA
1 shared publication- Ethan S. Sokol
Foundation Medicine , Cambridge, MA
1 shared publication
Latest Publications
- Open Access
- 19 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
Most colorectal (CRC) tumors are dependent on EGFR/KRAS/BRAF/MAPK signaling activation. ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated CRC tumors. Here we show that anti-EGFR but not anti-VEGF treatment enriches for emerging ARID1A mutations in CRC patients. In addition, we find that patients with ARID1A mutations, at baseline, are associated with worse outcome when treated with cetuximab- but not bevacizumab-containing therapies; thus, this suggests that ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies. We find that, ARID1A and EGFR-pathway genetic alterations are mutually exclusive across lung and colorectal cancers, further supporting a functional connection between these pathways. Our results not only suggest that ARID1A could be potentially used as a predictive biomarker for cetuximab treatment decisions but also provide a rationale for exploring therapeutic MAPK inhibition in an unexpected but genetically defined segment of CRC patients.
- 19 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Open AccessARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
Most colorectal (CRC) tumors are dependent on EGFR/KRAS/BRAF/MAPK signaling activation. ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated CRC tumors. Here we show that anti-EGFR but not anti-VEGF treatment enriches for emerging ARID1A mutations in CRC patients. In addition, we find that patients with ARID1A mutations, at baseline, are associated with worse outcome when treated with cetuximab- but not bevacizumab-containing therapies; thus, this suggests that ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies. We find that, ARID1A and EGFR-pathway genetic alterations are mutually exclusive across lung and colorectal cancers, further supporting a functional connection between these pathways. Our results not only suggest that ARID1A could be potentially used as a predictive biomarker for cetuximab treatment decisions but also provide a rationale for exploring therapeutic MAPK inhibition in an unexpected but genetically defined segment of CRC patients.
- 24 September 2020
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 59 (41) , 3982-3992
Dimerization Induced by C-Terminal 14–3–3 Binding Is Sufficient for BRAF Kinase Activation
The Ras-RAF-MEK-ERK signaling axis, commonly mutated in human cancers, is highly regulated to prevent aberrant signaling in healthy cells. One of the pathway modulators, 14-3-3, a constitutive dimer, induces RAF dimerization and activation by binding to a phosphorylated motif C-terminal to the RAF kinase domain. Recent work has suggested that a C-terminal “DTS” region in BRAF is necessary for this 14-3-3 mediated activation. We show that the catalytic activity and ATP binding affinity of the BRAF:14-3-3 complex is insensitive to the presence or absence of the DTS, whilst the ATP sites of both BRAF molecules are identical and available for binding. We also present a crystal structure of the apo BRAF:14-3-3 complex showing that the DTS is not required to attain the catalytically active conformation of BRAF. Rather, BRAF dimerization induced by 14-3-3 is the key step in activation, allowing the active BRAF:14-3-3 tetramer to achieve catalytic activity comparable to the constitutively active oncogenic BRAF V600E mutant.
- 24 September 2020
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 59 (41) , 3982-3992
Dimerization Induced by C-Terminal 14–3–3 Binding Is Sufficient for BRAF Kinase Activation
The Ras-RAF-MEK-ERK signaling axis, commonly mutated in human cancers, is highly regulated to prevent aberrant signaling in healthy cells. One of the pathway modulators, 14-3-3, a constitutive dimer, induces RAF dimerization and activation by binding to a phosphorylated motif C-terminal to the RAF kinase domain. Recent work has suggested that a C-terminal “DTS” region in BRAF is necessary for this 14-3-3 mediated activation. We show that the catalytic activity and ATP binding affinity of the BRAF:14-3-3 complex is insensitive to the presence or absence of the DTS, whilst the ATP sites of both BRAF molecules are identical and available for binding. We also present a crystal structure of the apo BRAF:14-3-3 complex showing that the DTS is not required to attain the catalytically active conformation of BRAF. Rather, BRAF dimerization induced by 14-3-3 is the key step in activation, allowing the active BRAF:14-3-3 tetramer to achieve catalytic activity comparable to the constitutively active oncogenic BRAF V600E mutant.